Revvity Health Sciences, Inc.

Revvity Health Sciences, Inc., doing business as PerkinElmer Inc., manufactures and services medical imaging products, laboratory analytical equipment, and scientific instrumentation for federal research, diagnostic, and operational programs as a prime contractor across 249 distinct federal agencies. The company operates as a subsidiary of parent Revvity Inc. and competes exclusively in full-and-open procurements—no set-aside categories recur across its footprint. Over the past five years, Revvity has captured 6,817 prime awards worth $875.3 million in combined potential value, with recent activity declining sharply (155 awards in 2022 to 10 in 2026 year-to-date), reflecting either a shift in customer demand patterns or a compressed award reporting cycle in the source.

Revvity's capability portfolio centers on equipment procurement, preventative maintenance, repair services, and consumable supplies for specialized laboratory instrumentation. Representative work includes a $9.263 million definitive contract from the Office of the Assistant Secretary for Preparedness and Response for the Multiplex, Accurate, Rapid, Testing for You (MARTY) diagnostic platform (September 2024); a $696,235 service and maintenance agreement with the National Center for Advancing Translational Sciences for Operetta CLS and Opera Phenix high-content imaging systems and associated equipment (September 2025); a $769,847 sole-source maintenance contract from the National Institute of Allergy and Infectious Diseases for two Operetta CLS and six Opera Phenix confocal microscopy systems (September 2026); and a $530,109 maintenance agreement with NCATS for multiple Opera Phenix and Operetta units (April 2024). The vendor also supplies consumables—HTRF assay kits, AlphaLISA reagent beads, scintillation cocktail, and radioactive tracers—to NIH institutes including NIAID, NIDA, and NHLBI. Service maintenance contracts dominate by volume and dollar value; equipment sales and reagent orders form a secondary revenue stream.

Customer concentration is pronounced. The top five customer agencies by potential value represent 14 percent of combined potential dollars: CDC Pittsburgh (204 awards, $55.5 million), CDC Acquisition Services (305 awards, $29.6 million), the Army Medical Command (216 awards, $18.5 million), EPA Office of Research and Development (85 awards, $8.3 million), and NCI (221 awards, $6.7 million). By award count, NIH Office of the Director leads with 402 awards, though at only $2.8 million potential value—a signal that many of those awards are small purchase orders for consumables or routine service calls. CDC Pittsburgh anchors the dollar volume ranking, reflecting Revvity's role as the incumbent maintenance provider for the agency's genomic sequencing and imaging platforms.

Revvity holds two IDVs: a $10 million single-award Blanket Purchase Agreement with the National Eye Institute for laboratory supplies, medical and scientific equipment, instruments, and radionuclides (awarded March 2024, through December 2026), and an $86,484 single-award Indefinite Delivery Contract with Naval Sea Systems Command for maintenance of a Nexion 2000C inductively coupled plasma mass spectrometer (awarded September 2022, through September 2025). The largest parent vehicle by task-order volume is the Scientific Equipment and Services contract framework, which houses 1,042 task orders valued at $561.8 million—the backbone of Revvity's federal delivery model. Top NAICS categories are Analytical Laboratory Instrument Manufacturing (3,265 awards) and Other Electronic and Precision Equipment Repair and Maintenance (1,797 awards), consistent with the vendor's end-to-end equipment and service posture.

Revvity's recompete exposure in the next twenty-four months is $18.4 million across 51 awards. Activity trajectory shows material decline: 155 awards in 2022 contracted to 10 awards year-to-date in 2026. Service Contract Inventory data (SCI-reportable contracts above $150,000) shows minimal federal services staffing—0.3 FTEs in FY2022, zero in FY2023, 0.1 FTEs in FY2024—with invoiced federal services revenue of $2.6 million across FY2022–2024. SCI-reportable government-paid hourly rates ran a median $1,734/hr, with senior labor pricing through $3,386/hr. The vendor operates as a prime on 100 percent of its captured awards; sub-engagement on SCI records is zero percent. Revvity subcontracts minimally: three named subs appear across recent years (Medical Science & Computing, Verus Research, and Consolidated Nuclear Security) in specialized technical roles under defense and national security primes, but sub work is negligible relative to the prime footprint. The vendor builds its own delivery teams for equipment installation, maintenance dispatch, and technical support, leveraging PerkinElmer-certified service engineers and proprietary diagnostic toolsets as competitive moats for sole-source renewals across NIH, CDC, and DoD customers.